Breakthroughs and Challenges in Pediatric Migraine Therapy Research

Challenges in Pediatric Migraine Research

Guidelines Derived from Adult Studies

Due to ethical and logistical challenges in pediatric research, guidelines for migraine treatments in children have predominantly been based on studies conducted with adults. Recent reviews have brought attention to significant advancements in this area, particularly the approval of new acute migraine therapies and the initiation of large-scale trials focused on children.

Prevalence of Migraines in Children

Migraines reportedly affect approximately 9.1% of children, with chronic migraines impacting around 2% of teenagers. Chronic migraines are characterized by experiencing more headache days than non-headache days over a three-month period. The exact causes of migraine attacks remain unclear, leading to a wide variety of available therapies aimed at alleviating their debilitating symptoms. These treatments can be categorized into acute, chronic, and preventative therapies.

Acute Migraine Therapy

Common Treatments

The most extensively studied acute migraine treatments include nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and acetaminophen, with ibuprofen demonstrating superior pain relief two hours post-administration. For patients who do not respond to NSAIDs, triptans are available as an alternative. Although triptans have been widely used in adults, initial trials in children yielded mostly unfavorable results. However, modifications to trial designs to incorporate significant placebo effects resulted in positive outcomes and subsequent FDA approval for pediatric use.

Risks of Overuse

It is critical to avoid overusing acute therapies, as taking these medications more than 15 days per month can lead to chronic migraines, particularly in adults. In cases where migraines persist for over 72 hours, they are referred to as status migrainosus, which may require emergency interventions and hospital admission. The primary treatment for children in such scenarios involves intravenous fluids, which are favored for their low risk and ease of administration, despite limited evidence regarding their effectiveness in pain reduction.

Chronic Migraine Therapy

Effective Medications

Several medications have shown promise in providing relief for chronic migraines. Dopamine receptor antagonists, such as prochlorperazine, have reported response rates of approximately 85% in some studies. Patients using this medication also noted fewer return visits than those on alternative dopamine receptor antagonists. For hospitalized patients, NSAIDs are administered intravenously, with ketorolac tromethamine being the only intravenous NSAID studied in children. One study indicated that ketorolac achieved at least a 50% reduction in pain for 55% of participants, compared to prochlorperazine.

Invasive Treatment Options

For longer-lasting relief, peripheral nerve blocks represent a more invasive treatment option. This procedure involves the injection of local anesthetics into the scalp’s surface. Although case series have reported benefits from peripheral nerve blocks for chronic migraines and post-traumatic headaches, placebo-controlled studies in pediatric populations are lacking.

Preventive Therapies

When headaches disrupt regular activities several days a week, preventive therapies should be considered. Unfortunately, research on preventive treatments for pediatric migraines is limited, with no FDA-approved medications available for children under 12 years.

The CHAMP Trial for Migraine Prevention in Children

Trial Overview

One significant initiative in preventive migraine research was the CHAMP trial, which compared the effectiveness of topiramate, amitriptyline hydrochloride, and placebo over a 24-week period for children with episodic and chronic migraines. Results indicated that 50% to 60% of participants experienced a 50% or greater reduction in headache days from baseline to the last four weeks of the study.

Study Findings and Implications

Despite these findings, the trial was halted early due to a lack of difference between treatment and placebo groups, with both medications exhibiting more adverse effects than the placebo. However, the authors recommend considering medications with low-risk profiles, as the strong placebo effect may still yield better outcomes than no treatment.

Natural Health Alternatives

Nutraceuticals and Psychological Methods

Nutraceuticals offer a low-cost and low-risk alternative to conventional pharmaceuticals, though evidence supporting their efficacy in preventing migraines is limited. Psychological approaches, such as cognitive behavioral therapy (CBT), can provide coping strategies for pain; however, restricted access to professionals has resulted in many studies utilizing self-administered CBT, yielding mixed outcomes.

Conclusion

The optimal guidelines for managing pediatric migraines should integrate both acute and preventive therapies. While significant advancements, such as FDA approval of triptans and the launch of larger-scale initiatives like the CHAMP trial, have been made, further research is essential to validate the effectiveness of these treatments in children. Future studies should continue to explore the impact of the strong placebo effect in both acute and preventive migraine therapies.

Written by Agustin Dominguez Iino, BSc
Reference: Patterson-Gentile C, Szperka CL. The Changing Landscape of Pediatric Migraine Therapy: A Review. JAMA Neurol. 2018 Mar 12. doi: 10.1001/jamaneurol.2018.0046.